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We believe that our patient suffered hypomagnesaemic, 
hypocalcaemic tetany consequent upon renal damage after 
prolonged and recurrent courses of intravenous aminogly- 
cosides. She had received more than 28 000 mg tobramycin 
over a 6-month period. Other possible contributory factors 
were malabsorption (faecal fat 8.1 g day- ‘), and treatment 
with sodium containing semi-synthetic penicillins, mainten- 
ance prednisolone (total dosage exceeding 2800 mg) and 
nebulized amphotericin [intravenous amphotericin can 
cause both glomerular and tubular renal damage (10) but 
there are no reports of hypomagnesaemia resulting from 
nebulized amphotericin B]. 
Although hypomagnesaemia can result from complex 
and interacting factors, aminoglycoside toxicity was the 
most likely cause in this case, damaging the renal tubules 
which subsequently leaked magnesium. We suggest that all 
patients with cystic fibrosis who receive prolonged and/or 
repeated courses of aminoglycosides should have regular 
monitoring of their serum magnesium levels. 
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Introduction 
Cushing’s Syndrome comprises symptoms and signs caused 
by prolonged exposure to high free plasma glucocorticoid 
levels. Patients have an increased susceptibility to infection, 
and it is felt that the risk of infection correlates with the 
degree of hypercortisolism (1). Consequently, opportunistic 
infection is less likely in patients with pituitary-dependent 
Cushing’s Syndrome than in patients with adrenal 
tumours or ectopic adrenocorticotrophic hormone (ACTH) 
production, who tend to have much higher cortisol 
secretion rates (1). 
Received 10 February 1997 and accepted in revised form 2 June 
1997. 
Correspondence should be addressed to: A. Hill, Department of 
Medicine, Queen Elizabeth Hospital, Birmingham, U.K. 
Case Report 
A 40-year-old Caucasian woman was admitted with a right 
femoral deep vein thrombosis (DVT), having developed 
severe proximal myopathy necessitating the use of a wheel- 
chair for the previous 4 months. Over the past 2 years, she 
had repeatedly failed to attend further investigations for 
new onset amenorrhoea and hypertension, the latter treated 
with a thiazide diuretic. She smoked 30 cigarettes per day 
but did not drink to excess. On physical examination, she 
had the classical signs of Cushing’s Syndrome including 
moon face, truncal obesity, buffalo hump, thin skin, easy 
bruising, wide purple striae, muscular weakness, acne, 
sweating, hirsutism and emotional lability (Plate 1). In 
addition, she had a large patch of fat necrosis over the 
lower abdomen leaking serous fluid and a 3 x 5 cm abscess 
in the right popliteal fossa, both present over the last 2 
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PLATE 1. Photograph revealing Cushingoid appearance. 
months. Examination of the chest revealed crackles in the 
right upper lobe. 
Serum electrolytes and blood sugar were normal. The 
haemoglobin concentration was 6.9 g dll ’ with a mean 
cell volume of 74 fl. Doppler ultrasound confirmed a DVT. 
The chest radiograph revealed extensive right upper lobe 
cavitation and sputum analysis revealed sputum smear- and 
culture-positive Mycobacterium tuberculosis fully sensitive 
to conventional anti-tuberculous chemotherapy. Similarly, 
smear- and culture-positive M. tuberculosis was identified 
from the bacteriology from the abscess in the popliteal fossa 
and abdominal fat necrosis. No source of infection was 
obtained. She had prior BCG vaccination and had no 
known contact with tuberculosis or foreign travel. A HIV 
antibody test was negative. 
Further tests confirmed she had Cushing’s Syndrome: 
three urinary free cortisol estimations were grossly elevated 
(5400, 5800 and 6500 nmol day- ‘, normal range 30-350) 
and there was loss of the normal diurnal variation in 
plasma cortisol [0900h cortisol 636 nmol 1 - i (200&700), 
0900h ACTH 15.5 ng I- i (~50) and 2300h cortisol 783 
(4140) 2300h ACTH 21.1 (<lo)]. Further tests suggested 
that the source of the hypercortisolism was pituitary in 
origin. On rifampicin treatment there was no suppression to 
high dose dexamethasone (2 mg six hourly for 48 h). There 
was suppression, however, when the rifampicin was stopped 
for 10 days prior to repeating the test (baseline cortisol 
578 nmol 1~ ‘, ACTH 20.9 ng l- ‘, and urinary free cortisol 
1354 nmol l- ’ reducing to 201, 22 and ~20, respectively). 
There was a brisk rise in ACTH following injection of 
corticotrophin releasing factor (baseline ACTH 43.5 peak- 
ing to 119 ng 1~ ’ after 15 min). Computed tomographic 
scanning of the pituitary fossa and abdomen were normal, 
but subsequent magnetic resonance imaging suggested the 
presence of a left-sided pituitary microadenoma. 
The patient was anticoagulated with warfarin for 3 
months for the DVT. She received standard anti- 
tuberculous treatment, but during treatment, she developed 
a large right pleural effusion requiring intercostal drainage. 
The area of abdominal fat necrosis continued to leak serous 
fluid necessitating a transfusion of eight units of blood, and 
subsequently surgery to excise the fat necrosis (histology 
revealed an ulcerated lesion with acid-alcohol-fast bacilli). 
She completed 6 months anti-tuberculous chemotherapy 
with good effect resulting in healed popliteal and abdominal 
wounds with resolution of the right upper lobe tuberculosis. 
Transethmoidal hypophysectomy was performed 2 months 
after the initial diagnosis was made. This confirmed the 
presence of a left sided microadenoma which was removed 
successfully. A post-operative 0900h plasma cortisol off all 
therapy was 130 nmol 1 - ’ confirming a biochemical cure. 
Discussion 
It is known that rifampicin interferes with the overnight 
dexamethasone suppression test making it uninterpretable, 
and it is recommended that rifampicin be stopped 15 days 
before carrying out the dexamethasone suppression test (2). 
The mechanism is thought to be induction of hepatic 
6-P-hydroxylase by rifampicin which increases the meta- 
bolic clearance of both dexamethasone and cortisol (3). 
Immune suppression increases the risk to infection as 
seen in renal, liver and cardiac transplantation, and patients 
treated with systemic steroids. In renal, liver and cardiac 
transplantation, the incidence of mycobacterial disease 
(especially atypical, extra-pulmonary and dissemination) 
is increased (4,5). The incidence of tuberculosis in patients 
treated with systemic steroids varies between 0 and 3% (6) 
and Millar et al. felt the risk of tuberculosis was 
highest in patients receiving doses of prednisolone above 
10 mg day ~ ’ particularly in association with additional 
immunosuppressive agents (7). 
Harvey Cushing’s original report (1932) indicated that 
‘the malady appears to leave the patients with a definite 
susceptibility to infections’ (8), but there have as yet been 
no cases of tuberculosis described. It is felt that the extent 
of immunological impairment and risk of different infec- 
tions correlates with the degree of hypercortisolism, and 
thus opportunistic infection is more likely in patients with 
adrenal tumours or ectopic ACTH production than 
patients with Cushing’s Disease (1). 
Graham et al. described 23 cases of opportunistic infec- 
tions in Cushing’s Syndrome (two cases had pituitary 
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adenomas and the rest were predominantly ectopic ACTH 
production or adrenal tumours), but there were no reported 
cases of tuberculosis (1). The opportunistic infections 
included Cryptococcus neoformans, Nocardia, Aspergillus 
fumigatus and Pneumocystsis carinii. Scully et al. reported a 
case of disseminated tuberculosis and aspergillosis found at 
post-mortem due to an adrenal tumour (9). 
Tuberculosis has not been described previously in 
Cushing’s Disease. Our patient was not diagnosed for 2 
years, and it appears that the prolonged exposure to 
hypercortisolism, due to Cushing’s Disease, and tuberculo- 
sis itself (active tuberculosis increases glucocorticoid 
activity which in turn suppresses cell mediated immunity) 
(lo), resulted in disseminated tuberculosis. 
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